Valuation of the benefits of risk-free blood. Willingness to pay for hemoglobin solutions.
The dream of artificial blood has existed since the 1960s. Disease-free hemoglobin solutions will be commercially available in 1991. A willingness-to-pay (WTP) survey was undertaken to assess the tangible and intangible benefits to the public from this new product. The positive results suggest that third-party payers should cover this benefit and assist the diffusion of this new technology. From the perspective of industrial marketing, results suggest that there will be little consumer price resistance for hemoglobin solutions within the suggested price range of +225-300 per unit. Management implications of this new product are discussed.
Eastaugh
S R
SR
George Washington University.
D001802:Blood Substitutes; D001803:Blood Transfusion / Q000191:economics*; D003132:Commerce; D003258:Consumer Behavior / Q000706:statistics & numerical data*; D003365:Costs and Cost Analysis; D004059:Diffusion of Innovation; D005069:Evaluation Studies as Topic; D008389:Marketing of Health Services; D014481:United States
D001802:Blood Substitutes